ACTIVATE YOUR
OWN DEFENSE

Latest news headline

08.10.2020

MVX-ONCO Explained

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194.

27.05.2021

CELL ENCAPSULATION COULD ENHANCE ANTIVIRAL VACCINES

Immunotherapy techniques developed in oncology to combat cancerous cells have great potential for fighting viruses. A research team from the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE), in Switzerland, in collaboration with MaxiVAX, a spinoff of both institutions, developed an innovative technology called « cell encapsulation ». Originally designed to stimulate immunity to fight cancer, the COVID-19 pandemic motivated the scientists to broaden the scope of their technology to test its effectiveness against viruses. The first results of a pre-clinical study are very encouraging and can be discovered in the journal Vaccines.

 English Français

22.02.2021

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership

GENEVA, Switzerland and MUNICH, Germany – Feb 22, 2021 — MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.

 English Français Deutsch

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194.

02.06.2020

COVID-19

Geneva study against SARS-COV-2 gets underway

Geneva University Hospitals (HUG), the University of Geneva (UNIGE), the Infectious Disease Research Centre at Laval University in Quebec (Canada) and MaxiVAX – a Geneva-based company specialising in biotechnology – are working together to develop a SARS-CoV-2 vaccine. This joint research programme aims to create a vaccine combining an immunostimulator and a specific coronavirus target, namely the spike surface protein. This is administered by intradermal injection with the immunostimulator, whose role is to produce an adjuvant capable of stimulating the immune system. It is implanted under the skin via cell encapsulation, a technology that is already undergoing Phase II clinical tests led by HUG in collaboration with MaxiVAX in the area of cancer immunotherapy.
The first pre-clinical tests for perfecting the vaccine will be carried out on mice in the coming weeks. If preliminary tests prove encouraging, a clinical trial could be set up in the near future.

26.11.2019

MaxiVAX awarded €2,785,000 European Commission grant and announces successful closing of its Series B 2 round for an amount of CHF 5 million

  • MaxiVAX wins grant among 94 projects funded out of 2,015 applications
  • Closing of Series B 2 round of CHF 5 million from new and existing investors
  • Funds used for Phase 2 cancer programs

MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.

The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194